Eli Lilly’s GLP-1 pill Foundayo alleviated sleep apnea in two late-stage studies, reducing breathing disruptions by 17.8 events per hour on the apnea-hypopnea index compared to 4.5 for placebo. Furthermore, 28% of patients achieved remission or mild disease, versus 13% on placebo, though it appears